{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:01:03Z","timestamp":1795075263168,"version":"4.10.2"},"reference-count":110,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Over the past decade, T-cell\u2013directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggest that these therapies may be associated with a high incidence of serious cardiovascular toxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these events is a major limitation to long-term survival after these treatments. This review examines the current state of evidence, including reported incidence rates, risk factors, mechanisms, and management strategies of cardiovascular toxicities after treatment with these novel therapies. We specifically focus on CAR-T and BTE therapies and their relation to arrhythmia, heart failure, myocarditis, bleeding, and other major cardiovascular events. Beyond the relationship between cytokine release syndrome and cardiotoxicity, we describe other potential mechanisms and highlight key unanswered questions and future directions of research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013849","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T16:35:06Z","timestamp":1729182906000},"page":"6282-6296","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Cardiovascular toxicities associated with novel cellular immune therapies"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-8677","authenticated-orcid":false,"given":"Malak","family":"Munir","sequence":"first","affiliation":[{"name":"1Department of Medicine, Ain Shams University Faculty of Medicine, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8917","authenticated-orcid":false,"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Ain Shams University Faculty of Medicine, Cairo, Egypt"},{"name":"2Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-8333","authenticated-orcid":false,"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[{"name":"3Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH"},{"name":"4Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"5","key":"2024122319302570500_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024122319302570500_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10343","key":"2024122319302570500_bib3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"2024122319302570500_bib4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024122319302570500_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024122319302570500_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024122319302570500_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024122319302570500_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024122319302570500_bib9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"2024122319302570500_bib10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024122319302570500_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2024122319302570500_bib12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T\u00a0cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2024122319302570500_bib14","unstructured":"National Library of Medicine. Accessed 2 November 2024. https:\/\/clinicaltrials.gov\/."},{"issue":"22","key":"2024122319302570500_bib15","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"2024122319302570500_bib16","doi-asserted-by":"crossref","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"18","key":"2024122319302570500_bib17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024122319302570500_bib18","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024122319302570500_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/annonc\/mdw604","article-title":"Causes of death among cancer patients","volume":"28","author":"Zaorsky","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"2024122319302570500_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"8","key":"2024122319302570500_bib21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024122319302570500_bib22","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","article-title":"Cardiac effects of anticancer therapy in the elderly","volume":"32","author":"Accordino","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024122319302570500_bib23","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"2024122319302570500_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"2024122319302570500_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2024122319302570500_bib26","doi-asserted-by":"crossref","first-page":"e001743","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T\u00a0cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"2024122319302570500_bib30","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"2024122319302570500_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"2","key":"2024122319302570500_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024122319302570500_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10299","key":"2024122319302570500_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"2024122319302570500_bib35","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024122319302570500_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024122319302570500_bib37","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024122319302570500_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2024122319302570500_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2024122319302570500_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024122319302570500_bib41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line Therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Eng J Med"},{"issue":"8","key":"2024122319302570500_bib42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10297","key":"2024122319302570500_bib43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2024122319302570500_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2024122319302570500_bib45","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2024122319302570500_bib46","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"2024122319302570500_bib98","volume-title":"KYMRIAH (tisagenlecleucel)","year":"2024"},{"key":"2024122319302570500_bib99","volume-title":"YESCARTA (axicabtagene ciloleucel) suspension for intravenous infusion","year":"2023"},{"issue":"7","key":"2024122319302570500_bib100","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024122319302570500_bib101","volume-title":"TECARTUS (brexucabtagene autoleucel)","year":"2024"},{"key":"2024122319302570500_bib102","volume-title":"BREYANZI (lisocabtagene maraleucel)","year":"2024"},{"issue":"10402","key":"2024122319302570500_bib103","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"2024122319302570500_bib104","volume-title":"ABECMA (idecabtagene vicleucel)","year":"2024"},{"issue":"11","key":"2024122319302570500_bib105","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2024122319302570500_bib106","volume-title":"CARVYKTI (ciltacabtagene autoleucel)","year":"2024"},{"key":"2024122319302570500_bib108","volume-title":"BLINCYTO (blinatumomab) for injection, for intravenous use","year":"2022"},{"issue":"3","key":"2024122319302570500_bib109","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO Expanded Access Study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv"},{"key":"2024122319302570500_bib83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"14","key":"2024122319302570500_bib110","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"2024122319302570500_bib115","volume-title":"TECVAYLI (teclistamab-cqyv) injection, for subcutaneous use","year":"2022"},{"key":"2024122319302570500_bib111","volume-title":"COLUMVI (glofitamab-gxbm) injection, for intravenous use","year":"2023"},{"key":"2024122319302570500_bib116","volume-title":"LUNSUMIO (mosunetuzumab-axgb) injection for intravenous use","year":"2022"},{"key":"2024122319302570500_bib112","volume-title":"EPKINLY (epcoritamab-bysp) injection, for subcutaneous use","year":"2023"},{"issue":"12","key":"2024122319302570500_bib27","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"2024122319302570500_bib113","volume-title":"AMTAGVI (lifileucel)","year":"2024"},{"issue":"4","key":"2024122319302570500_bib47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11899-020-00585-2","article-title":"Advances in supportive care for acute lymphoblastic leukemia","volume":"15","author":"Cook","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"2024122319302570500_bib48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2024122319302570500_bib49","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"2024122319302570500_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024122319302570500_bib51","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"issue":"2","key":"2024122319302570500_bib53","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"2","key":"2024122319302570500_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2024122319302570500_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2024122319302570500_bib56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2024122319302570500_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"2024122319302570500_bib58","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"2024122319302570500_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2018-02-769000","article-title":"Inflammation, von Willebrand factor, and ADAMTS13","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024122319302570500_bib60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"8","key":"2024122319302570500_bib61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"7","key":"2024122319302570500_bib62","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"2024122319302570500_bib63","unstructured":"IL-1 receptor antagonist to prevent severe chimeric antigen receptor T-cell related encephalopathy syndrome ClinicalTrials.gov identifier: NCT04205838. Updated 5 July 2024. Accessed 1 January 2024. https:\/\/clinicaltrials.gov\/study\/NCT04205838."},{"key":"2024122319302570500_bib64","unstructured":"Phase 2 pilot study to evaluate efficacy and safety of anakinra to prevent CD19-targeted CAR-T cell-related cytokine release syndrome (CRS) and neurotoxicity in patients with B cell lymphoma. Updated 18 July 2024. ClinicalTrials.gov identifier: NCT04359784. Accessed 1 January 2024. https:\/\/clinicaltrials.gov\/study\/NCT04359784."},{"key":"2024122319302570500_bib65","unstructured":"Pilot study of anakinra to mitigate CAR-T toxicity in subjects with relapsed or refractory large B-cell lymphoma ClinicalTrials.gov identifier: NCT04432506. Updated 31 May 2024. Accessed 1 January 2024. https:\/\/clinicaltrials.gov\/study\/NCT04432506."},{"issue":"1","key":"2024122319302570500_bib66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2024122319302570500_bib67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1200\/OP.22.00713","article-title":"Cardiotoxicities of novel therapies in hematologic malignancies: chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy","volume":"19","author":"Marar","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"25","key":"2024122319302570500_bib68","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2024122319302570500_bib69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"12","key":"2024122319302570500_bib70","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA Adverse Events Reporting System Analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024122319302570500_bib71","doi-asserted-by":"crossref","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"13","key":"2024122319302570500_bib72","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2024122319302570500_bib73","doi-asserted-by":"crossref","first-page":"e002303","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"2024122319302570500_bib74","doi-asserted-by":"crossref","first-page":"691064","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"2024122319302570500_bib75","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Pathophysiology of sepsis-induced cardiomyopathy","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2024122319302570500_bib28","first-page":"86","article-title":"Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma","volume":"44","author":"Fradley","year":"2020","journal-title":"J\u00a0Immunother"},{"issue":"8","key":"2024122319302570500_bib76","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024122319302570500_bib77","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00277-018-3495-2","article-title":"Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed\/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party","volume":"98","author":"Jung","year":"2019","journal-title":"Ann Hematol"},{"issue":"6","key":"2024122319302570500_bib78","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2024122319302570500_bib79","doi-asserted-by":"crossref","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","article-title":"Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study","volume":"69","author":"Korell","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2024122319302570500_bib80","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024122319302570500_bib81","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2024122319302570500_bib82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","article-title":"BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a Bispecific T-Cell Engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)","volume":"124","author":"Goekbuget","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2024122319302570500_bib84","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024122319302570500_bib85","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2024122319302570500_bib87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"16","key":"2024122319302570500_bib89","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"2024122319302570500_bib90","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"41","key":"2024122319302570500_bib88","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2024122319302570500_bib92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2024122319302570500_bib94","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"2024122319302570500_bib95","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024122319302570500_bib96","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024122319302570500_bib93","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2024122319302570500_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option","volume":"6","author":"Rohaan","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2024122319302570500_bib97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6282\/2346981\/blooda_adv-2024-013849-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6282\/2346981\/blooda_adv-2024-013849-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T14:30:51Z","timestamp":1734964251000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/24\/6282\/518220\/Cardiovascular-toxicities-associated-with-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":110,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013849","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}